Is trastuzumab injection (subcutaneous injection) (Herceptin Hylecta) taken orally or injected?

Trastuzumab injection (subcutaneous ) (Herceptin Hylecta) is a sterile, preservative-free, colorless to slightly yellow, clear to milky white solution. It is provided in a single-dose vial for subcutaneous administration. It can be used to treat metastatic breast cancer and its adjuvant treatment. It can be used alone or in combination with other chemotherapy drugs. Trastuzumab injection (subcutaneous ) is supplied in single-dose vials containing 600 mg of trastuzumab and 10,000 units of hyaluronidase per 5 mL.

Trastuzumab is a humanizedIgG1 monoclonal antibody that selectively binds to the extracellular domain of the human epidermal growth factor receptor 2 protein HER2 with high affinity. Trastuzumab is produced in mammalian cell (Chinese hamster ovary) cultures by recombinant DNA technology. The molecular weight of trastuzumab is approximately 148kDa. Hyaluronidase (recombinant human) is an endoglycosidase used to increase the dispersion and absorption of co-administered drugs when administered subcutaneously. It is a glycosylated single-chain protein produced by mammalian (Chinese hamster ovary) cells and contains a DNA plasmid encoding a soluble fragment of human hyaluronidase (PH20). The molecular weight of hyaluronidase (recombinant human) is approximately 61kDa.

It is understood that the original drug of trastuzumab injection (subcutaneous injection) has been launched in China, but the specific price and other relevant information are not yet clear. Since the drug has been on the market for a short time, it has not been included in the scope of medical insurance. At present, there are no generic drugs of Trastuzumab injection (subcutaneous injection) produced and marketed. For more information and specific prices of Trastuzumab injection (subcutaneous injection), please consult a medical consultant.